Perinatal Mental Health: Sertraline in Pregnancy

Clinical Scenario

Sarah Collins, 32, a part-time teacher, has just discovered she is 6 weeks pregnant and is worried about her sertraline 100mg. She has a history of severe postnatal depression after her first child three years ago, which took a year to resolve. She stopped her sertraline three days ago without medical advice due to fears about harming the baby and is already feeling more anxious. The pregnancy was planned and wanted.

What This Case Tests

Providing evidence-based reassurance about SSRI safety in pregnancy; conducting a risk-benefit analysis that accounts for the patient's psychiatric history; recognising the danger of abrupt SSRI cessation; making an appropriate perinatal mental health referral; creating a monitoring plan spanning pregnancy and the postnatal period.

Common Mistakes Trainees Make

The three most common mistakes in this case are: agreeing with the patient's decision to stop sertraline without providing the evidence that continuing is likely safer than stopping, failing to recognise her history of severe postnatal depression as a major risk factor for recurrence that changes the risk-benefit calculation significantly, and not making an urgent perinatal mental health team referral given her high-risk profile. A fourth error is providing vague reassurance rather than specific data about sertraline safety in pregnancy.

The Consultation Challenge

This case involves a pregnant woman already established on sertraline for depression or anxiety who is now worried about the safety of continuing her medication during pregnancy. It sits at the intersection of perinatal mental health, prescribing safety, and shared decision-making — one of the most nuanced consultation types in the SCA.

The patient's fear is understandable: she has read online that antidepressants cause birth defects, and well-meaning family members may be reinforcing this concern. The evidence, however, is reassuring: sertraline is one of the most extensively studied SSRIs in pregnancy, with a strong safety profile. The NICE guidance on antenatal mental health is clear that untreated maternal depression and anxiety carry greater risks to the pregnancy (preterm birth, low birth weight, impaired maternal-infant bonding) than SSRI treatment.

The critical error trainees make is either abruptly stopping the sertraline (exposing the patient to relapse and withdrawal during a vulnerable period) or dismissing the patient's concerns about medication safety. Neither approach reflects the balanced, evidence-based, patient-centred care the examiner expects.

Your role is to provide an honest risk-benefit discussion. Acknowledge the small absolute risks (neonatal adaptation syndrome in approximately 30% of exposed neonates, mostly mild and self-limiting; no confirmed teratogenic risk with sertraline at standard doses), contextualise them against the risks of untreated maternal mental illness, and support the patient's decision — whichever way she chooses.

You should also assess her current mental health status. Has the pregnancy itself triggered a change in symptoms? Is she sleeping, eating, bonding with the pregnancy? Are there thoughts of self-harm? The perinatal period is high-risk for mental health deterioration.

Time check: Spend the first 3 minutes exploring her concerns and what she has read or been told. By minute 5, assess her current mental health status. Use minutes 6-9 for the risk-benefit discussion with clear, jargon-free explanations. Reserve the final 3 minutes for the decision and follow-up planning with her midwife and perinatal mental health team.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you explore the source of her concerns (internet, family, previous healthcare professional), her current mental health status (PHQ-9/GAD-7 equivalent questioning), the history of her depression or anxiety (how severe, how many episodes, previous relapses when stopping medication), and her understanding of the medication. You must also screen for perinatal-specific risks: thoughts of self-harm, bonding concerns, and the impact of anxiety on her experience of pregnancy.

Clinical Management and Medical Complexity: This domain is heavily weighted. Examiners expect you to know the evidence on sertraline in pregnancy: no confirmed increased risk of major malformations, approximately 30% risk of neonatal adaptation syndrome (jitteriness, feeding difficulties, usually self-limiting within 48 hours), and the importance of delivery unit awareness. You must balance this against the risks of stopping: relapse of depression in pregnancy (approximately 68% relapse rate when SSRIs discontinued in pregnancy per key studies), withdrawal symptoms, and the downstream risks of untreated maternal depression. Demonstrating knowledge of the perinatal mental health referral pathway and the role of the specialist perinatal team shows strong management.

Relating to Others: Examiners watch whether you validate the patient's concerns rather than dismissing them as unfounded, whether you explain risks in absolute rather than relative terms (making them meaningful), and whether you genuinely support shared decision-making. The patient should feel she has been given honest information to make her own choice, not pressured in either direction.

Example Opening

Strong opening: "Hello, I understand you have some concerns about your sertraline now that you're pregnant. That's a really important thing to discuss, and I want to make sure we go through this properly. Can you start by telling me what's been worrying you?"

This validates her concern as legitimate and signals that you will give it proper time and attention.

When presenting the evidence: "The good news is that sertraline is one of the best-studied antidepressants in pregnancy, and the evidence is reassuring. There's no confirmed increase in birth defects. There is a chance — about 1 in 3 — that the baby might be a bit unsettled in the first couple of days after birth, but this usually settles on its own. What I'd also like us to think about is what might happen to your mental health if we stop the medication."

Avoid: "There's nothing to worry about — sertraline is perfectly safe in pregnancy." (Oversimplifies the evidence and dismisses her concerns).

How This Appears in the SCA

Perinatal mental health is a high-yield SCA topic spanning two RCGP domains: mental health and gender/reproductive health. This case tests your ability to provide evidence-based medication counselling, balance competing risks, and demonstrate awareness of specialist referral pathways. Examiners particularly assess whether you can communicate risk data clearly without causing additional anxiety.

Key Statistic

Women with a history of postnatal depression have a 30-50% risk of recurrence in subsequent pregnancies. Sertraline shows no increased risk of major birth defects in large-scale studies involving thousands of pregnancies.

Relevant Guidelines

• NICE CG192: Antenatal and postnatal mental health — recommends continuing effective antidepressants in pregnancy when risks of stopping outweigh medication risks
• recommends specialist perinatal mental health referral for women with previous severe postnatal depression.

Frequently Asked Questions

Is sertraline safe to take during pregnancy?

Sertraline is one of the most extensively studied SSRIs in pregnancy. There is no confirmed increased risk of major congenital malformations. The main known risk is neonatal adaptation syndrome, affecting approximately 30% of exposed neonates, presenting as jitteriness, irritability, and feeding difficulties that are usually mild and self-limiting within 48 hours. NICE recommends that the decision to continue or stop should be based on an individual risk-benefit assessment, not a blanket rule.

What are the risks of stopping antidepressants during pregnancy?

Research shows that approximately 68% of women who discontinue SSRIs during pregnancy relapse into depression. Untreated maternal depression is associated with preterm birth, low birth weight, impaired maternal-infant bonding, and increased risk of postnatal depression. Additionally, abrupt discontinuation can cause withdrawal symptoms. These risks must be weighed against the relatively small risks of continuing treatment.

How do I explain medication risks in pregnancy without causing more anxiety?

Use absolute numbers rather than relative risks. "About 1 in 3 babies may be a bit unsettled for a day or two" is much less alarming than "there is a 30% increased risk of neonatal complications." Contextualise the risk: most babies exposed to sertraline are born healthy and develop normally. Frame the discussion as a choice between two sets of risks, not a choice between risk and safety — untreated depression carries its own pregnancy risks.

Should I involve the perinatal mental health team in this decision?

Yes — referral to or liaison with the specialist perinatal mental health team is good practice and demonstrates strong Clinical Management in the SCA. They can provide ongoing support, shared care with the midwife, and a plan for the postnatal period when mental health risk increases further. Mentioning this in the exam shows you understand the multidisciplinary approach to perinatal care.

What if the patient decides to stop sertraline despite my advice?

Respect her autonomy. If she decides to stop, plan a supervised gradual reduction (never abrupt cessation), increase monitoring frequency, ensure she knows the early signs of relapse, and have a clear plan for restarting if symptoms return. Document the discussion and her informed decision. The examiner wants to see that you support the patient's choice while maintaining a safety net.